

Proposal for decision by the Annual General Meeting of Active Biotech AB (publ) on April 21, 2004 authorising the Board to decide on new share issues

The Board proposes that the Annual General Meeting authorise the Board to decide on one or more occasions during the period up to the next Annual General Meeting to increase in the company's share capital by at most SEK 60,000,000 through the issue of a total of not more than 6,000,000 new shares, with or without preferential rights for existing shareholders to participate in the issue, and with or without stipulations regarding payment in kind, set-off or other conditions stated in Chapter 4, paragraph 6 of the Swedish Companies Act.

Dilution effects

If issues are conducted waiving the rights of existing shareholders, the issue price shall correspond to the market price of the share. Full exercise of the authorisation will result in a dilution effect (following full exercise of existing warrants) to 14.6 percent.

Reasons for the proposal

The purpose of the authorisation is to facilitate the financing, commercialisation and development of the company's projects and to provide flexibility in commercial partnership negotiations.

Majority requirement

A decision in accordance with the proposal requires the support of shareholders representing at least two thirds of both the shares represented at the Annual General Meeting and of the votes cast.

Lund, March 22, 2004
Active Biotech AB (publ)
The Board